ArticleBMC neurology2025
Effectiveness and safety of Risdiplam for types 1-3 spinal muscular atrophy in a single center.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundRisdiplam has demonstrated efficacy in various types of 5q-spinal muscular atrophy (SMA) during clinical trials, yet real-world data remain limited. This study evaluated its effectiveness and safety in Chinese SMA children and explored influencing factors.
methodsThis retrospective study included genetically confirmed SMA patients treated with risdiplam at Children’s Hospital of Fudan University from August 2021 to August 2024. We analyzed data on the age of onset, types, SMN2 copy number, treatment initiation age and duration, respiratory and feeding status, motor function and safety.
resultsA total of 12 SMA patients (4 type 1, 7 type 2, 1 type 3) were included, with a median age of 14.4 months (range: 1.7-161.7 months), was evaluated over a follow-up period of 8–18 months after starting risdiplam. Motor function improvements were well noted in 11 children, with Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders scores increasing by 1.73 points monthly. Notably, nine patients attained new World Health Organization motor milestones after an average of 9.8 months post-treatment. Subgroup analysis indicated that younger age and earlier intervention were associated with more pronounced clinical benefits. Adverse events, primarily respiratory infections were the most common adverse event but did not lead to deaths or treatment discontinuations, likely attributable to the underlying disease rather than risdiplam—were observed but did not result in treatment discontinuation or mortality.
conclusionRisdiplam treatment is effective and safe in Chinese pediatric SMA patients, enhancing motor function and facilitating new milestones achievement. Early diagnosis and treatment are vital for maximizing benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.